Showing results (801-810 of 868) with videos related to

Sort By:
Pageof 87
Nature Communications|July 12, 2023
Structural and photophysical characterization of the small ultra-red fluorescent proteinAtanu Maiti, Cosmo Z Buffalo, Saumya Saurabh, et al.
Nature Communications|October 14, 2018
Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplexDavid R Calabrese, Xiang Chen, Elena C Leon, et al.
Analytical Chemistry|September 21, 2017
Development of a Cigarette Tobacco Filler Standard Reference MaterialLane C Sander, Jeanita S Pritchett, Yasmine C Daniels, et al.
Journal of General Internal Medicine|March 16, 2016
Individual Versus Team-Based Financial Incentives to Increase Physical Activity: A Randomized, Controlled TrialMitesh S Patel, David A Asch, Roy Rosin, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters, Yu Wang, Nu Lai, et al.
British Journal of Pharmacology|May 22, 2025
Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2α dependent transcriptionPatrick G Schweickert, Dana Piovesan, Casey G Mitchell, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different DiseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 17, 2024
Role of the histone variant H2A.Z.1 in memory, transcription, and alternative splicing is mediated by lysine modificationAnas Reda, Luca A Hategan, Timothy A B McLean, et al.
The EMBO Journal|February 15, 2024
Shared and distinct mechanisms of UBA1 inactivation across different diseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Pageof 87